Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03599570 · ClinicalTrials.gov registry record · NA

The STOP-HPV Trial 2: Performance Feedback Intervention

A NA study of Vaccination and Immunization, sponsored by University of California, Los Angeles.

Completed
Registry status
NA
Development phase
48
Enrollment target
1
Study location

NCT03599570 is a NA study of Vaccination and Immunization that has completed, run by University of California, Los Angeles. The registered enrollment target is 48 participants, below the 10,229-participant average among 12 other Vaccination trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03599570, a NA study of Vaccination and Immunization, has completed, sponsored by University of California, Los Angeles.

COMPLETED
Registry status
NA
Development phase
48 participants
Enrollment target
1
Study location

Study Summary

Most adolescents who receive human papillomavirus (HPV) vaccine are vaccinated in pediatric practices, yet missed opportunities (MOs) for HPV vaccination occur often and lead to low HPV vaccination rates. This cluster randomized clinical trial (RCT) will test the effectiveness (and cost-effectiveness) of the addition of performance feedback (period 2) to training providers previously received on HPV vaccine communication (period 1) to reduce MOs and increase HPV vaccination rates.

Conditions Studied

Interventions

  • BEHAVIORAL STOP-HPV performance feedback intervention

Study Locations (1)

Illinois

  • American Academy of Pediatrics - Itasca

Trial Details

FieldValue
Enrollment Target 48 participants
Start Date 2018-08-07
Est. Completion 2020-03-06
Phase NA

What the Registry Record Tells You About NCT03599570

The ClinicalTrials.gov registry entry for NCT03599570 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 10,229-participant average among 12 other Vaccination trials with a reported enrollment target (100% lower). The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Vaccination appearing as the primary indexed condition, and to 1 intervention - of which STOP-HPV performance feedback intervention is the first listed.

NCT03599570 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.

Frequently Asked Questions

What is clinical trial NCT03599570 about?

NCT03599570 is a clinical study titled "The STOP-HPV Trial 2: Performance Feedback Intervention". Most adolescents who receive human papillomavirus (HPV) vaccine are vaccinated in pediatric practices, yet missed opportunities (MOs) for HPV vaccination occur often and lead to low HPV vaccination rates. This cluster randomized clinical trial (RCT) will test the effectiveness (and cost-effectivenes...

What is the current status of trial NCT03599570?

This trial is currently completed. It is a NA study. The enrollment target is 48 participants. The study started on 2018-08-07. Estimated completion is 2020-03-06.

What conditions does trial NCT03599570 study?

This clinical trial studies the following conditions: Vaccination, Immunization.

What interventions are being tested in trial NCT03599570?

The interventions under investigation include: STOP-HPV performance feedback intervention (BEHAVIORAL).

Who is sponsoring clinical trial NCT03599570?

This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03599570 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Vaccination

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.